UK’s NHS Backs World’s Costliest Drug Libmeldy for the Treatment of Rare Disease MLD
XTalks
FEBRUARY 14, 2022
The UK’s National Health Service (NHS) has recommended the use of Libmeldy for the treatment of the rare genetic disease metachromatic leukodystrophy (MLD). After further discussion with Orchard Therapeutics, the NHS negotiated an additional, undisclosed discount on the drug, allowing the health agency to now offer it to patients.
Let's personalize your content